Song, Zhengbo

D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results

Li, Z., Song, Z., Zhao, Y., Wang, P., Jiang, L., Gong, Y., Zhou, J., Jian, H., Dong, X., Zhuang, W., et al. (2023) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 88

Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations

Cheng, G., Song, Z., & Chen, D. (2016) · OncoTargets and Therapy

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 77

LBA33 A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation

Zhou, C., Li, W., Song, Z., Zhang, Y., Zhang, Y., Huang, D., Yang, Z., Zhou, M., Mao, R., Huang, C., et al. (2023) · Annals of Oncology

Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK Pathways

Cited by 59

Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial

Shi, Y., Fang, J., Xing, L., Yao, Y., Zhang, J., Liu, L., Wang, Y., Hu, C., Xiong, J., Liu, Z., et al. (2025) · Nature Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 42

Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations

Wang, W., Lian, B., Xu, C., Wang, Q., Li, Z., Zheng, N., Liu, A., Yu, J., Zhong, W., Wang, Z., et al. (2024) · The Innovation

Melanoma and MAPK PathwaysLung Cancer Treatments and Mutations

Cited by 14